Stručni rad

Perindopril - a landmark in hypertension and cardiovascular disease management.

Darja Milovanovič Jarh ; Krka, d.d., Novo mesto, Slovenija
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d.d., Novo mesto, Slovenija
Mateja Grošelj ; Krka, d.d., Novo mesto, Slovenija

Sažetak

Hypertension is a major cardiovascular and
cerebrovascular risk factor and is highly prevalent throughout
the world, affecting 50% of people over 60 years of age. Angiotensin-converting enzyme (ACE) inhibitors are the gold
standard in the treatment of hypertension. However, there exist important differences among the available ACE inhibitors.
Perindopril is distinguished based on specific characteristics,
such as long duration of action, 24-hour blood pressure control, high lipophilicity, and high tissue ACE affinity. Moreover,
clinical studies investigating the effects of perindopril on morbidity and mortality have provided evidence of its benefits
along cardiovascular disease continuum. Since inappropriate
treatment was one of the most important reasons for the inadequate blood pressure control, the high efficacy and safety
of Perineva® (Krka’s perindopril) and its availability in a variety of dosage forms, strengths and fixed-dose combinations
might facilitate the management of hypertension and improve
compliance among the Croatian patients

Ključne riječi

perindopril; hypertension; cardiovascular disease; efficacy; safety

Hrčak ID:

71485

URI

https://hrcak.srce.hr/71485

Datum izdavanja:

30.3.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.987 *